77749-81-6
Chemical Structure
RX-RA 85
- CAS No.: 77749-81-6
- Formula:C22H27N7OS2
- Molecular Weight:469.63
IUPAC Name: 4-(8-(phenethylthio)-2-(piperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl)thiomorpholine 1-oxide
InChIKey: SFLXZGLWKMACEP-UHFFFAOYSA-N
SMILES: O=S1CCN(C2=NC(=NC=3C(=NC=NC32)SCCC=4C=CC=CC4)N5CCNCC5)CC1
Biological Activity: RX-RA 85 is an orally active phosphodiesterase modulator that exerts antiplatelet and antitumor effects by elevating intracellular cAMP levels, inhibiting platelet and tumor cell PDE activity, and modulating cytoskeletal organization. RX-RA 85 can be used in studies of rat breast cancer and metastatic tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RX-RA 85 | RX-RA 85 is an orally active phosphodiesterase modulator that exerts antiplatelet and antitumor effects by elevating intracellular cAMP levels, inhibiting platelet and tumor cell PDE activity, and modulating cytoskeletal organization. RX-RA 85 can be used in studies of rat breast cancer and metastatic tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lichtner RB, et al. The pyrimido-pyrimidine derivatives RA 233 and RX-RA 85 affect growth and cytoskeletal organization of rat mammary adenocarcinoma cells. European journal of cancer & clinical oncology. 1987 Sep;23(9):1269-75.
- [2]. Lichtner RB, et al. Effects of the pyrimido-pyrimidine derivative RX-RA 85 on metastatic tumor cell-vascular endothelial cell interactions. Clinical & experimental metastasis. 1987 Sep;5(3):219-31.
- [3]. Lichtner R, et al. Enhancement of the immune response to sheep erythrocytes in mice by phosphodiesterase-inhibiting dipyridamole derivatives. J Immunopharmacol. 1984;6(1-2):43-55.